Hematopoietic stem cell transplantation for systemic sclerosis with rapid improvement in skin scores: Is neoangiogenesis occurring?

R. K. Burt, Yu Oyama, A. Traynor, K. Quigley, M. Brush, J. Rodriguez, W. G. Barr

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Systemic sclerosis (SSc) is presumed to be an immune-mediated vasculopathy of unknown etiology. SSc is unresponsive to most immune-modulating therapies except for intravenous cyclophosphamide, which is reported to demonstrate some benefit. We, therefore, dose-escalated cyclophosphamide to 200 mg/kg and added rabbit ATG 7.5 mg/kg along with infusion of unselected hematopoietic stem cells to minimize the cytopenic interval. Engraftment occurred rapidly (day 8) with minimal unexpected toxicity, no infections, and unexpectedly rapid improvement in the modified Rodnan Skin Score.

Original languageEnglish (US)
Pages (from-to)S65-S67
JournalBone Marrow Transplantation
Volume32
DOIs
StatePublished - Jan 1 2003

Keywords

  • Hematopoietic stem cell transplantation
  • Scleroderma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Hematopoietic stem cell transplantation for systemic sclerosis with rapid improvement in skin scores: Is neoangiogenesis occurring?'. Together they form a unique fingerprint.

  • Cite this